SSA therapy markedly enhanced the expression of p-CREB and BDNF, decreased the expression of Bax and Caspase-3, elevated the expression of Bcl-2, and inhibited the death of hippocampal neurons, therefore ameliorating depression-like behavior in PSD rats. Here, BCL2 is linked to major depressive disorder.